Purpose: To investigate 
INTRODUCTION
Among the gastrointestinal cancers, colon cancer is one of most prevalent types [1] . Owing to the drastic alterations in human life styles, the incidence of cancer has significantly increased globally. Studies have reported that colon cancer is the second major reason for cancer-related deaths among all malignant tumors [2] . Currently, the treatment of colon cancer involves surgery, followed by chemotherapy. However, the prognosis for colon cancer is very poor, and the mortality rate is high [3] . Therefore, there is an urgent need to develop novel treatment strategies or explore novel targets to limit the increasing incidence of colon cancer. MicroRNAs (miRNAs) include a large family of small noncoding RNAs that are involved in the inhibition of protein synthesis by binding to different sites in the 3'-untranslated region (3'-UTR) of target genes. Therefore miRNAs exhibit remarkable biological significance and play a role in diverse cellular process [4, 5] .
Among several human miRNAs associated with cancers, hsa-microRNA-383-5p (miR-383) has been reported to be principally upregulated. Thus, it has been reported to promote tumor progression in several cancers, including, but not limited to, gastric cancer and glioma [6, 7] .
In the present study, the expression of miR-383 was determined in different colon cancer cell lines, and miR-383 was explored as a potential therapeutic target for the treatment of colon cancer.
EXPERIMENTAL Colon cancer cell lines and culture conditions
All the chemicals and reagents were obtained from Sigma-Aldrich Co. (St. Louis, MO, USA) unless otherwise mentioned. Primary and secondary antibodies were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Six human colon cancer cell lines, CCL-233, CL-188, CL-231, HTB-37, HTB-39, and CRL-7280, and one normal cell line, CRL-1459, were purchased from Type Culture Collection of Chinese Academy of Sciences (Shanghai, China). Cell culture was carried in RPMI-1640 medium containing 10% fetal bovine serum, appropriate antibiotics, with maintenance in a humidified atmosphere containing 5 % CO 2 . All of the reagents were procured from Hyclone.
RNA isolation, cDNA synthesis, and expression analysis
Total RNA was isolated using the RNeasy kit according to the manufacturer's instructions. Quality check of the RNA samples was performed by measuring the absorbance using a NanoDrop® ND-1000 spectrophotometer (NanoDrop Technologies), calculating the 260 nm/280 nm ratio and separation on 1 % agarose gels. DNA contamination was removed by DNase I (Fermentas) treatment. cDNA was synthesized using the RevertAid cDNA synthesis kit (Fermentas) according to the manufacturer's protocol.
The relative quantification method (ΔΔ-CT) was used to determine the quantitative variation among the replicates examined. β-Actin was used as a positive control to normalize the data.
Inhibition of miR-383 in colon cancer cells
The inhibitor of human miR-383 (MiR383-In, 107 units/mL) and its non-specific miRNA lentivirus (MiR-C, 107 units/mL) were obtained from RiboBio (RiboBio, China). CL-188 cells were incubated with lentiviral particles (10 mL/1000 cells; multiplicity of infection = 10-15) and polybrene (8 mg/mL) for 48 h. Thereafter, the media were replaced, and CL-188 cells were incubated for another 3-7 days for stabile transduction. The cells were then passaged and preserved in vitro for further analysis.
Proliferation assay
Oral cancer CL-188, microRNA-inhibited CL-188 cancer cells, and normal CRL-1459 were separately seeded into 96-well plates, with each well containing approximately 5, 000 cells and the cells permitted to grow for 5 days. Thereafter, cell proliferation was examined using the cell proliferation assay kit (Promega USA) according to the manufacturer's guidelines. At every 24-h interval, 15 mL of MTT solution was administrated to each well for 2 h at 37 °C. The absorbance was recorded at 570 nm using a spectrophotometer.
Apoptosis assay
Colon cancer CL-188, microRNA-inhibited CL-188 cancer cells, and normal CRL-1459 cells were separately seeded at density of 2 10 5 cells/well in 6-well plates and were treated with different concentrations of cisplatin and then were incubated for 24 h. Apoptosis was examined by incubating the cells in 6-well plates for 24 h with DAPI.
The cells were then washed with PBS, fixed in 10 % formaldehyde, followed by another wash with PBS. The DAPI-stained cells were then examined by fluorescence microscopy. For annexin V/PI staining, a similar procedure to that of DAPI was followed except the cells were treated with annexin V/PI and were investigated by flow cytometry.
Identification of the miR-383 target
To gain insight into the potential target of miR-383, the TargetScan search program was used.
Western blotting
Total protein from the cancer cells was isolated using RIPA lysis buffer. The proteins were quantified using the BSA protein assay kit, and equal protein extracts from each group were resolved by sodium dodecyl sulfatepolyacrylamide gel electrophoresis, followed by transfer to a polyvinylidene fluoride membrane. Next, the membrane was blocked with 5 % nonfat milk and incubated at room temperature for 1 h. Thereafter, the membranes were incubated with the primary antibody at 4 °C overnight, followed by washing in washing buffer and incubation with the secondary antibody for 1 h. The protein bands of interest were visualized using the ECL Advanced Western Blot Detection Kit.
Statistical analysis
The experiments were repeated three times, and the values were expressed as means ± SD. GraphPad 7 software was used for statistical analysis. The values were considered significant at *p < 0.01, **p < 0.001, and ***p < 0.0001, as appropriate.
RESULTS

miR-383 is upregulated in colon cancer cell lines
The expression of miR-383 was determined in six different oral cancer cell lines (CCL-233, CL-188, CL-231, HTB-37, HTB-39, CRL-7280) and one normal cell line CRL-1459 (Figure 1 ) by quantitative RT-PCR analysis. The results of this study revealed that the expression of miR-383 was considerably upregulated in all the oral cancer cell lines compared with that in the control. These results of expression analysis indicated that miR-383 may prove to be an important therapeutic target.
Inhibition of miR-383 promotes growth inhibition
To understand the role of miR-383 in colon cancer, its expression was inhibited in colon cancer CL-188 cells through lentiviral transduction. The results indicated that the inhibition of miR-383 caused significant inhibition of the growth of colon cancer cells as evident from the proliferation assay (Figure 2 ). These results suggest that miR-383 is required for the proliferation of colon cancer cells. The experiments were carried out in triplicate and were expressed as means ± SD. The values were considered significant at *p < 0.01, **p < 0.001, and ***p < 0.0001
Inhibition of miR-383 promotes apoptosis
The results indicated that the inhibition of miR-383 results in the inhibition of cell growth. Therefore, to ascertain whether the antiproliferative effects are due to the induction of apoptosis, DAPI staining was carried out. Interestingly, the results indicated that the inhibition of miR-383 in colon cancer CL-188 cells led to the triggering of apoptosis (Figure 3) . Furthermore, the apoptotic cell populations were examined by annexin V/PI double staining. The results showed that the apoptotic cell distribution was 39.6 % in miRNA-inhibited cells compared with 2.61 % in control CL-188 cells (Figure 4) .
Inhibition of miR-383 induces cell cycle arrest
The cell cycle phase distribution in miR-383 silenced and control CL-188 colon cancer cells was further determined. The results suggested that miR-383 inhibition promotes G2/M cell cycle arrest as evident by the accumulation of a higher number of CL-188 oral cancers in the G2 phase of the cell cycle ( Figure 5 ). To identify the downstream target gene of miR-383, the target scan (www.targetscan.org) server was used. CASP2 was observed to be a potential target gene of miR-383. The 3ʹ-UTR DNA segment of CASP2 was found to be complimentary to the binding of miR-383 (Fig.  5A) . Next, to further confirm that CASP2 is the actual target of miR-383, the expression of the CASP2 gene in colon cancer CL-188 and miRNA-inhibited CL-188 cancer cells was examined by western blotting. The results revealed that miR-383 inhibition considerably enhanced CASP-2 gene expression in CL-188 cells, further validating that the CASP-2 gene is the potential target of miR-383 in colon cancer cells. 
DISCUSSION
It is now well established in the literature that miRNAs play vital roles in human cancer development and its progression through different stages [8] . The expression of miRNAs may be either enhanced or suppressed depending on whether they promote or suppress the tumorigenesis and progression of cancers. Recently, miRNAs have been considered important therapeutic targets for the management of several types of cancers [9] . miR-383 has been reported to play vital roles in human cancers such as ovarian cancer [10] . However, the exact role and underlying mechanism of miRNA-383 in the development of cancer progression have not been thoroughly studied.
In the present study, the expression of miR-383 was investigated in six different colon cancer cell lines and one normal cell line. The results of this study revealed that the expression of miR-383 was highly upregulated in all the colon cancer cell lines. The results of this study agree with previous study data wherein the expression of miR-383 was observed to be highly enhanced in several cancers. For instance, Liu et al reported that the expression of miR-383 was highly enhanced in ovarian cancer cells [10] . More interestingly, some studies have even reported that the expression of miR-383 is down-regulated in cancers like gastric cancer and glioma [6, 7] . These results, as well as those of previous studies, clearly indicate that miR-383 may be an important therapeutic target.
To confirm the role of miR-383 in colon cancer, silencing of microRNA expression in CL-188 colon cancer cells was performed by lentiviral transduction. The inhibition of miR-131 was demonstrated to inhibit the cell proliferation of CL-188 cells compared with that in the control. Furthermore, to gain insights into the mechanism by which miR-383 promotes the inhibition of cell proliferation, DAPI staining was carried out. The results indicated that the inhibition of miR-383 triggered apoptosis in CL-188 cells. The latter finding was further confirmed by annexin V/PI staining, which revealed that miR-383 caused 39 % of apoptosis compared with 3.4 % in the control. Apoptosis is an important mechanism by which cancerous cells are removed from the body. Several anticancer agents have been reported to exhibit anticancer activities via the induction of apoptosis. In addition, apoptosis is an important mechanism to avoid the development of drug resistance [11] . Moreover, besides apoptosis, cell cycle arrest is considered an important mechanism by which anticancer agents exert their effects [12] .
The results of the present study clearly showed that the inhibition of miR, leading to G2/M cell cycle arrest in colon cancer CL-188 cells, was quite evident from the increased number of colon cancer cells in the G2 phase of the cell cycle. Next, the online software TargetScan was used to delimit the potential target of miR-383. The results showed CASP-2, a member of cysteine protease family, was the downstream target gene of miR-383. Recent studies have demonstrated that CASP-2 protein triggers cell death in human cancer cells, possibly via the suppression of fatty acid synthase [13] . To further confirm the involvement of CASP-2 in miR-383-prompted cell death, we investigated the expression of CASP-2 in CL-188 cells with silenced miR-383. The results indicated that the expression of CASP-2 was highly enhanced in these cells, confirming the involvement of CASP-2 in microRNAtriggered cell death in colon cancer cells.
CONCLUSION
The findings of this study indicate that miR-383 may be an important target to stem the increasing incidence of colon cancer. Thus, drugs that target miR-383 and inhibit its expression can potentially be developed for the treatment of colon cancer.
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